Brian D D, Tilley B C, Labarthe D R, O'Fallon W M, Noller K L, Kurland L T
Mayo Clin Proc. 1980 Feb;55(2):89-93.
Reports in the popular press have suggested that exposure to diethylstilbestrol (DES) is followed by an abnormally high incidence of breast cancer. The reports were based on a reanalysis of data not considered ominous originally; and both data and analyses are summarized here. In addition, new data are presented on mothers of young women enrolled in the National DESAD Project at its Mayo Clinic Center. Among 408 women given DES, there were 8 confirmed instances of breast cancer, in comparison with an expected number of 8.1, based on breast cancer incidence rates among parous women in the local population. A previous case-control study of the possible association of antihypertensive therapy and breast cancer in the local population revealed DES exposure in 10% of the breast cancer group and 12% of the controls. These apparently negative results clearly indicate a need of further studies of the alleged effect of DES.
大众媒体的报道表明，接触己烯雌酚（DES）后患乳腺癌的发病率异常高。这些报道基于对原本不被视为不祥的数据的重新分析；此处对数据和分析进行了总结。此外，还提供了在梅奥诊所中心参与国家DESAD项目的年轻女性母亲的新数据。在408名服用DES的女性中，有8例确诊乳腺癌，而根据当地人群中经产妇的乳腺癌发病率，预期病例数为8.1例。此前一项关于当地人群中抗高血压治疗与乳腺癌可能关联的病例对照研究显示，乳腺癌组中有10%的人接触过DES，对照组中有12%的人接触过DES。这些明显为阴性的结果清楚地表明需要对所谓的DES效应进行进一步研究。
